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Abstract
Several  lines  of  evidence  indicate  that  pre-fibrillar  assemblies  of  amyloid- (A)polypeptides  such  as 
soluble oligomers or protofibrils rather than mature, end-stage amyloid fibrils cause neuronal dysfunction  
and  memory  impairment  in  Alzheimer’s  disease  (AD).  This  suggests  that  reducing  the  prevalence  of  
transient intermediates by small molecule mediated stimulation of amyloid polymerization might decrease  
toxicity. Here, we demonstrate the acceleration of Afibrillogenesis through the action of the orcein-related  
small molecule O4, which directly binds to hydrophobic amino acid residues in Apeptides and stabilizes  
the  self-assembly  of  seeding-competent,  -sheet-rich  protofibrils  and  fibrils.  Strikingly,  O4-mediated  
acceleration of amyloid fibril formation efficiently decreased the concentration of small, toxic A oligomers in  
complex, heterogeneous aggregation reactions. In addition, O4 treatment suppressed inhibition of long-term  
potentiation by A oligomers in hippocampal brain slices. These results support the hypothesis that small,  
diffusible pre-fibrillar amyloid species rather than mature fibrillar aggregates are toxic for mammalian cells.
1
Introduction
Accumulation of  extracellular amyloid  plaques is  a 
key  feature  of  Alzheimer’s  disease  (AD) 
pathogenesis  1. Amyloid plaques are mainly formed 
of amyloid- (A) polypeptides of 39-42 amino acids, 
which are produced by proteolytic  cleavage of  the 
amyloid- precursor  protein  (APP),  a  membrane 
protein of largely unknown cellular function 2.
A monomers self-assemble into amyloid fibrils  by 
nucleation-dependent polymerization, a process that 
is accelerated by the addition of preformed amyloid 
fibrils  3. The formation of  -sheet-rich amyloid fibrils 
is  a  complex  multistep  process  associated  with 
cellular toxicity 4. It involves the assembly of various 
transient  and  intransient,  on-  and  off-pathway 
aggregate  species,  whose  structures,  sizes  and 
biological  activities  are  not  well  defined.  In  vitro 
studies have demonstrated that A monomers can 
convert  into  small,  -sheet-rich  oligomers  and 
protofibrils  that are on-pathway to the assembly of 
ordered amyloid fibrils  5,6. In addition, evidence was 
presented  that  A monomers  at  low temperatures 
can assemble into spherical, non--sheet oligomers, 
suggesting  that  they  are  off-pathway  aggregation 
products  7.  At  higher temperatures however,  these 
structures, transform readily into larger  -sheet-rich 
aggregates 7, indicating that structural conversion of 
non--sheet  Aoligomers into  -sheet-rich amyloid 
fibrils is possible. Small soluble, pre-fibrillar amyloid 
assemblies  such  as  A oligomers  cause  memory 
impairment  and  are  likely  to  be  more  toxic  than 
large,  end-stage,  amyloid  fibrils 2,8.  Discriminating 
among different  types  of  A aggregate  species  is 
therefore an important challenge to clarify the role of 
transient  oligomers  and  protofibrils  in  amyloid 
pathogenesis 4.
Biochemical and cell biological  studies indicate that 
amyloid  formation  pathways  can  be  manipulated 
with  small  molecules 9 Osmolytes  such  as 
trimethylamine N-oxide or glycerol as well as short 
peptides were shown to accelerate A fibrillogenesis 
10,11,  while  small  molecules  such  as  scyllo-inositol 
stabilize the formation of oligomers and protofibrils 
12.  In  contrast,  compounds  such  as  dopamine  or 
calmidazolium chloride were found to block amyloid 
fibrillogenesis 13-15. Substances selectively inhibiting 
A oligomerization 16,  redirecting amyloid formation 
pathways  17,18 or  remodeling  preformed  amyloid 
structures  19 were  also  reported.  Thus,  small 
molecules can be powerful tools for the modulation 
of amyloid formation cascades, stabilizing aggregate 
species  or  influencing  structural  changes  in 
aggregate pathways 20.
If  small, diffusible aggregation products are indeed 
the  toxic  species  in  AD  2,  accelerating  nucleation 
and  fibril  assembly  with  small  molecules  should 
reduce  their  toxicity.  To  test  this  hypothesis,  we 
have  searched  for  compounds  that  promote  A 
polymerization using a membrane filter assay. Here, 
we show that the natural compound mixture orcein 
and the related substance O4 are potent stimulators 
of A fibrillogenesis. Strikingly, compound-mediated 
amyloid  polymerization  was  accompanied  by  a 
dramatic reduction of toxic on-pathway aggregation 
intermediates. Detailed biochemical and biophysical 
studies  revealed  that  O4  directly  binds  to 
hydrophobic  regions  in  the  amyloid- 1-42  (A42) 
peptide  which  are  critical  for  efficient  amyloid 
polymerization 21. Our data indicate that O4 binding 
to A42  peptides stabilizes the assembly of  -sheet-
rich  protofilaments  that  efficiently  nucleate  the 
formation  of  amyloid  fibrils  3.  The  potential 
implications of these results for the treatment of AD 
and other amyloid diseases are discussed.
Results
Identification of A aggregation stimulators. 
In order to find chemical  compounds that promote 
A42 amyloidogenesis, a membrane filter retardation 
assay  (FRA)  was  established  that  allows  the 
quantification  of  large,  SDS-stable  protein 
aggregates.  It  is  illustrated  in  the  Supplementary 
Results (Supplementary Fig. 1a). Using this method, 
we  screened  a  focused  library  of  300  chemical 
compounds  that  were  previously  identified  as 
modulators  of  polyglutamine-mediated  huntingtin 
exon  1  aggregation  22.  We  detected  6  A42 
aggregation-promoting  compounds,  three  of  which 
shared  a  phenoxazine  structure.  The  natural  dye 
orcein,  which  most  effectively  accelerated 
spontaneous A42 aggregation  in vitro, was studied 
further (Fig. 1a and b, Supplementary Fig. 1b).
Orcein  is  a  mixture  of  closely  related  substances 
such  as  the   and  -amino-orceins  and 
orceimines  (1 –  6,  Supplementary  Fig. 1b)  23.  In 
order  to  identify  a  pure  compound that  stimulates 
A42 aggregation,  we  searched  for  orcein-related 
small  molecules  in  compound  libraries  and 
databases.  18  chemical  compounds  were  finally 
selected and tested (Supplementary Table 1),  and 
the  substance  2,8-bis-(2,4-dihydroxy-phenyl)-7-
hydroxy-phenoxazin-3-one,  termed  O4  (7),  was 
identified as a potent  A42 aggregation accelerator 
(Fig.  1a  and  b).  Quantitative  analysis  of  time-
resolved aggregation data revealed that O4 reduces 
the  lag  phase  of  A42 polymerization  (Sup 
Supplementary  Fig. 2a),  suggesting  that  it  targets 
early  aggregate  species  in  the  amyloid  formation 
cascade  3.  No  stimulation  of  aggregation  was 
observed  by FRA when the control  proteins APP, 
Hsp70 and Hsp90 were incubated for 4 d at 37°C 
with O4 (Supplementary Fig. 2b), indicating that the 
effect on  A42 peptides is specific and O4 does not 
promote  the  aggregation  of  unrelated  human 
proteins. Finally, the aggregation-promoting effect of 
O4  was  confirmed  with  more  physiological  A42 
concentrations (100 nM, Supplementary Fig. 2c and 
d).
O4 promotes assembly of -sheet-rich 
amyloid fibrils. 
As FRAs do not  discriminate  between fibrillar  and 
non-fibrillar  aggregates,  we  next  examined  the 
morphology of O4-generated protein assemblies by 
transmission  electron  microscopy  (TEM).  After  an 
incubation period of 4 d, worm-like A42 protofibrils 24 
with a length of ~30-150 nm and a diameter of ~5 
nm  were  predominantly  detected  in  untreated 
aggregation reactions (Fig.  1c). In contrast,  mostly 
longer amyloid  fibrils  (>500 nm) were observed in 
O4-treated samples, indicating accelerated amyloid 
formation.  A  similar  result  was  obtained  after  an 
incubation period of 7 d (Fig. 1c). Quantification 
of  fibrils,  protofibrils  and  oligomers  after  48  h 
confirmed  these  results  (Fig.  1d).  The  amount  of 
long amyloid fibrils (27%) was significantly larger (p 
< 1*10-5)  in  O4 treated samples than in  untreated 
control  samples  (1.3%).  At  the  same  time,  the 
fraction of oligomeric structures was reduced in O4-
treated aggregation reactions (p < 1*10-4).
Previous studies have demonstrated that  insoluble 
A42  fibrils  have  a  characteristic  cross--sheet 
conformation 25. Therefore, we investigated whether 
O4 treatment influences the structure of A42 amyloid 
fibrils using circular dichroism (CD) spectroscopy 18. 
We found that both O4-treated and untreated A42 
fibrils have CD spectra characteristic of -sheet-rich 
structures  (Fig.  1e),  indicating  that  compound-
mediated acceleration of A42 aggregation does not 
substantially  alter  fibril  conformation.  Next,  the 
conversion  of  unstructured A42 monomers into  -
sheet-rich aggregates was investigated. The change 
in CD signal at 218 nm over the course of 3,000 s 
was  monitored  for  O4-treated  and  untreated  A42 
peptides. A monoexponential data fit yielded a time 
constant of   = 150 ± 40 s for O4-treated samples, 
while a time constant of  = 350 ± 30 s was obtained 
for  untreated  samples,  indicating  that  O4 
accelerates  the  transition  of  unstructured  A42 
molecules into larger  -sheet-rich  aggregates (Fig. 
1f).
We  also  investigated  whether  O4-generated  A42 
fibrils  are  seeding-competent  structures.  Amyloid 
fibrils  were  produced  in  vitro in  the  presence and 
absence of O4 and added as seeds to an excess of 
unpolymerized A42 monomers. The formation of  -
sheet-rich  amyloid  fibrils  was  monitored  over  time 
using a Thioflavin T (ThT) dye binding assay 26. We 
found  that  both  O4-generated  A42  seeds  and 
untreated seeds accelerate  amyloid  polymerization 
(Fig. 1g), indicating that O4 treatment results in the 
formation of seeding-competent A42 structures.
Finally, the effect of O4 on template-mediated A42 
aggregation  was  confirmed  using  a  cell-based 
assay.  CHO  cells  overexpressing  mutant  human 
APP  protein  15 were  treated  with  preformed  A42 
fibrils 19,27, and subsequently incubated for 48 h with 
5  M  O4.  Formation  of  SDS-stable,  insoluble 
Aaggregates was monitored by FRA. The amount 
of insoluble A aggregates in O4 treated cells was 
4-fold higher than in untreated ones (Fig. 1 h and 
Supplementary  Fig. 2e),  indicating  that  the 
compound stimulates A polymerization in cell-free 
and cell-based assays.
O4 promotes formation of stable amyloid 
aggregates. 
The  stability  of  amyloid  structures  in  compound-
treated A42 aggregation reactions was analyzed by 
SDS-PAGE  and  silver  staining  (Fig.  2a).  In  the 
absence  of  O4,  aggregation  products  resolved  to 
monomers (~4 kDa),  small  oligomers (~10-12 and 
14-16 kDa), medium-size oligomers (~100-150 kDa) 
and  large  aggregates  (>250  kDa)  in  SDS  gels. 
However,  in  the  presence  of  the  compound  the 
relative  amount  of  medium-size,  SDS-stable 
oligomers  and  large  aggregates  was  increased, 
while the amounts of monomers and small oligomers 
were  decreased  (Fig.  2a).  This  supports  the  view 
that  O4 treatment promotes the formation of  large 
SDS-stable fibrillar structures (Fig. 1c and d) that do 
not  efficiently  disassemble  under  denaturing 
conditions.
We  then  investigated  whether  O4  treatment 
influences  the  protease  resistance  of  A42 fibrils. 
Aggregates generated in the presence or absence of 
O4 (4  -  21 d  at  37°C)  were  treated  with  different 
concentrations of proteinase K (30 min at 37°C) and 
subsequently analyzed by FRA. We found that SDS 
and proteinase K resistant A42  aggregates appear 
much  faster  in  the  presence  of  O4  than  in  its 
absence  (Fig.  2b),  supporting  the  results  with 
denaturing SDS-gels (Fig. 2a).
O4 converts A42 oligomers into SDS-stable 
aggregates. 
To examine whether O4 converts A42 oligomers into 
fibrils,  we  first  tested  whether  it  binds  to  different 
types  of  aggregate  species.  Peptide  preparations 
highly  enriched  in  unstructured  A42  monomers  18, 
spherical, -sheet-rich oligomers 28 or large -sheet-
rich amyloid fibrils  18 were produced and character-
ized by ThT fluorescence (Supplementary Fig. 3a), 
atomic  force  microscopy  (Supplementary  Fig. 3b) 
and  CD  spectroscopy  (Supplementary  Fig. 3c). 
Then, these samples were incubated with  O4 and 
spotted  onto  a  nitrocellulose  membrane.  After 
washing with  buffer O4 binding was examined. As 
O4 is a blue dye, its binding to amyloid aggregates 
can be detected colorimetrically (Fig. 2c). We found 
that  O4  readily  stains  -sheet-rich  oligomeric  and 
fibrillar  A42  aggregates,  while  monomers  were 
hardly  colored, indicating  that  the  compound 
preferentially  associates  with  -sheet-rich  amyloid 
assemblies. Membranes were finally analyzed using 
the anti-A antibody 6E10 (Supplementary Fig. 3d 
and e), demonstrating that comparable amounts of 
A42 preparations were spotted.
We  next  investigated  whether  O4  is  covalently 
cross-linked to -sheet-rich A42 assemblies, using a 
nitro-tretrazolium blue (NBT) staining assay  29. This 
method was shown recently to allow the detection of 
A42-bound  EGCG  molecules  18.  We  found  that 
EGCG but  not  O4 treated aggregates  are stained 
with NBT (Supplementary Fig. 3f), indicating that O4 
does not promote the cross-linking of A42 peptides. 
This result was also confirmed by incubation of A42 
assemblies with trifluor acetic acid (TFA), indicating 
that both O4 treated and untreated A42 aggregates 
are  dissolved  equally  well  by  the  solvent 
(Supplementary Fig. 3g).
To  assess  the  affinity  of  O4  to  -sheet  rich  A42 
oligomers,  compound  (0.4  –  200  µM)  treated 
aggregate  species  (equivalent  to  monomer 
concentrations of 3, 6 and 12 µM) were spotted onto 
nitrocellulose  membranes.  Binding  of  O4  to  A42 
oligomers  was  quantified  colorimetrically 
(Supplementary  Fig. 4a).  Quantitative  analysis  of 
data revealed half-maximal binding (EC50) constants 
of 50 ± 2 µM, 25 ± 1 µM, and 3.5 ± 0.1, respectively 
(Fig. 2d), which indicates that a single site binding 
model is not sufficient to explain compound binding. 
A cooperative binding model with a Hill coefficient of 
n = 4, however, allowed a reasonable representation 
of  data,  suggesting  that  O4  binding  to  oligomers 
requires  4  A42 molecules.  No  or  very  weak  O4 
binding was observed for control  proteins such as 
APP,  Hsp70  and  Hsp90  (Supplementary  Fig. 4b), 
indicating  that  the  compound  preferentially 
associates with A42 oligomers.
We  then  investigated  whether  O4  treatment 
influences the assembly of small A42  oligomers  30. 
A42  monomers were incubated for 24 h at 6-8°C in 
the  presence  and  absence  of  O4;  formation  of 
oligomers  was  subsequently  analyzed  by  TEM.  In 
soluble fractions of untreated aggregation reactions 
large  numbers  of  predominantly  spherical  A42 
oligomers with a diameter of 5-15 nm were observed 
(Fig. 2e), while such structures were rarely detected 
in O4 treated samples. Compound treated samples, 
however,  contained multiple protofibrillar  structures 
and amorphous A42 aggregates, suggesting that O4 
binding converts  oligomers  into  larger  aggregates. 
This result was confirmed when pellet fractions were 
analyzed  by  TEM  (Fig.  2e).  O4  treated  fractions 
contained long amyloid fibrils. Such structures were 
undetectable  in  untreated  fractions,  which  rather 
contained smaller protofibrillar aggregates (Fig. 2e). 
The  effect  of  O4  on  early  -sheet-rich  aggregate 
species  was  also  visible  by  SDS-PAGE  and 
immunoblotting.  Compound  treatment  in  a 
concentration-dependent  manner  stimulated  the 
conversion of  small  A42 oligomers and protofibrils 
into larger SDS-stable amyloid aggregates (Fig. 2f), 
supporting the results observed by TEM (Fig. 2e).
Finally, we examined the effect of O4 on oligomers 
that are recognized by the conformation-specific A11 
antibody 31. Soluble A42 peptides were incubated in 
the presence and absence of O4 for 48 h at 37°C; 
the  resulting aggregate  species  were  analyzed  by 
dot blotting. A11-reactive oligomers were detected in 
the absence but not in the presence of the chemical 
compound  (Fig.  2g),  suggesting  that  O4  either 
masks the  epitope  for  antibody  binding or  coverts 
A11-reactive oligomers into larger structures which 
cannot be detected with this antibody 31.
O4 binds to hydrophobic regions in A42 
peptides. 
To  define  potential  O4  binding  regions  in  A42, 
peptide arrays 32 were produced and probed with the 
chemical  compound  (Supplementary  Fig. 5a,  Fig. 
3a). We found that O4 most strongly interacts with 
short  A42 peptides  that  contain  non-polar, 
hydrophobic  amino  acids  (e.g.,  peptide  12: 
VHHQKLVFFA,  aa  12-21  or  peptide  24: 
VGSNKGAIIG, aa 24-33), while peptides with polar 
amino acids (e.g., peptide 1: DAEFRHDSGY, aa 1-
10) were recognized very weakly or not at all (Fig. 
3a). This suggests that hydrophobic regions in A42 
peptides are preferentially targeted by the chemical 
compound. 
We  next  investigated  whether  the  position  of 
hydrophobic amino acids in peptides influences O4 
binding.  Two  short  peptides  were  synthesized  (A: 
KLVFFAE,  aa  16-22  of  A42 and  B:  EFAVFLK,  a 
scrambled  version  of  A)  and  O4  binding  was 
quantified  colorimetrically.  We  observed  that  O4 
readily  interacts  with  peptide  A  but  not  with  the 
control  peptide  B  (Supplementary  Fig. 5b  and  c), 
indicating that the compound interaction requires a 
certain  order  of  hydrophobic  amino  acids.  In 
comparison, the unspecific dye amido black detects 
both peptides equally well on filter membranes. 
Finally, we investigated the interaction between O4 
and  A40 peptides  by  NMR  spectroscopy.  We 
employed  A40 in  these  experiments  as  its 
aggregation  propensity  is  considerably  reduced  in 
comparison  to  A42,  making  it  more  amenable  to 
solution state NMR studies  3.  15N-labeled A40 was 
titrated  with  O4,  and  1H-15N  HSQC  spectra  were 
recorded.  Fig.  3b  shows  the  spectrum  obtained 
using  a  4-fold  molar  excess  of  O4.  Resonances 
involving  residues  17-20  and  31-37  exhibited 
pronounced  shifts  when  compared  to  resonances 
obtained in the absence of O4 (Fig. 3c), confirming 
the results with peptide arrays (Fig. 3a). Thus, our 
studies  demonstrate  that  O4  specifically  targets 
hydrophobic  regions  critical  for  efficient  amyloid 
polymerization 33 in A40 and A42 peptides.
Previous  studies  indicate  that  effects  of  small 
molecules on amyloidogenesis might be caused by 
compound aggregates  34. We therefore investigated 
whether O4 forms aggregates in aqueous solution. 
Analytical ultracentrifugation revealed that ~30% of 
O4 molecules in solution are aggregated and have 
an apparent mass of 10-20 kDa (Supplementary Fig. 
6a),  suggesting  that  larger  O4  aggregates  rather 
than monomers might promote A42  polymerization. 
To test  this hypothesis,  we removed the large O4 
aggregates  from  aqueous  solutions  by  filtration 
using  a  3  kDa  cut-off  membrane  (Supplementary 
Fig. 6a) and subsequently analyzed the resulting O4 
solutions in established A42 aggregation assays. We 
found that both filtered and unfiltered O4 solutions 
readily promote spontaneous amyloid polymerization 
in cell-free assays (Supplementary Fig. 6b and c), 
suggesting  that  high  molecular  weight  O4 
aggregates are not a prerequisite for the compound 
effects on A42 aggregation.
Finally, we applied NMR to investigate the potential 
structures of O4 molecules in aqueous solutions. We 
observed that the 1H-NMR spectra of O4 molecules 
in  filtered  and  unfiltered  solutions  are  almost 
identical  (Supplementary  Fig. 6d).  Moreover,  an 
equilibrium between an O4:A complex and soluble 
O4  and  A molecules  was  observed  by  NMR  in 
titration  experiments,  arguing  against  a  strong 
contribution  of  aggregated  O4  molecules  to  A 
binding.
O4 changes the affinity of antibodies for 
A42 fibrils. 
To examine whether O4 influences the morphology 
of  A42 fibrils,  compound-generated  structures 
(incubation for 5 d at 37°C) were analyzed with dot 
blot assays using the monoclonal anti-A antibodies 
6E10 and 4G8 35. We observed that 4G8 binding to 
O4-generated  A42 aggregates  was  reduced 
compared to untreated aggregates (Fig. 4a and b), 
suggesting  that  the  compound  alters  the  antibody 
binding to  amino  acids  18-22  in  A42 peptides.  In 
contrast,  no  such  effect  was  observed  with  the 
antibody  6E10  that  specifically  recognizes  the  N-
terminal amino acids 4-9 in A42 peptides. 
We  also  examined  whether  O4-generated  A42 
aggregates can be detected with  the conformation 
specific antibody B10 that preferentially recognizes 
amyloid  fibrils  but  does  not  bind  to  monomers  or 
small oligomers  36. As shown in Fig. 4c and d, O4 
treatment  results  in  A42 aggregate  species  with 
reduced B10 immunoreactivity,  suggesting that the 
antibody epitope on the surface of A42 aggregates 
is altered upon compound binding. 
Predicting the binding regions of O4 on A42 
fibrils. 
Using  a  computational  docking  approach,  we 
assessed how O4 might interact with a 3D structural 
model of A42 fibrils 25,7. To introduce some flexibility 
for the ligand the docking method Glide was applied 
37. Remarkably, in all adequate docking solutions the 
compound O4 was placed parallel to the long axis of 
amyloid  fibrils,  connecting  4-5  -sheet  units  (Fig. 
5a).  This  suggests  that  O4  promotes 
amyloidogenesis  because  it  stabilizes  the 
intermolecular  interactions  of  multiple  A42 
molecules.
Our docking studies predicted that O4 preferentially 
targets  three hydrophobic  binding grooves (aa 20-
21, 33-35 and 35-37) on the surface of A42 fibrils 
(Supplementary  Table  2),  suggesting  that  the 
compound has  more  than  one  favourable  docking 
site  on  amyloid  fibrils  (Fig.  5a  and  b).  A  detailed 
analysis  revealed  that  the  conjugated  -electron 
system of the planar oxazine ring in O4 most likely is 
critical for its association with hydrophobic grooves 
on  the  surface  of  A42 fibrils.  In  case  of  the  A42 
binding site at aa 20-21 the oxazine ring of O4 might 
directly  interact  with  the  aromatic  rings  of 
phenylalanine  20  (F20,  Fig.  5c),  while  at  binding 
sites aa 33-35 and 35-37 an interaction between the 
oxazine  ring  and  the  glycines  33  and  37  is  most 
likely. However, at all three favourable docking sites 
hydrogen bonds between hydroxyl groups in O4 and 
peptide carbonyl groups may also contribute to the 
compound interaction.
Finally, we also modeled docking of the O4 related 
compounds  5-methlybenzene-1,3-diol  (O5), 
phenoxazine (O6) and 7-hydroxy-phenoxazin-3-one 
(O8)  that  do  not  promote  spontaneous  A42 
aggregation  (Supplementary  Tables  1  and  2). 
Modelling predicted that the compounds O5 and O8, 
similar to O4, bind to the hydrophobic regions in A42 
fibrils  (aa  20-21,  33-35  and  35-37),  while  the 
compound  O6  most  likely  does  not  associate 
(Supplementary Table 2). This suggests that the di-
hydroxy-phenyl groups in O4, which are linked to the 
phenoxazinone unit and are absent from O8, might 
be  critical  for  its  aggregation  promoting  effect  on 
A42 molecules.
Acceleration of fibril formation reduces A42 
toxicity. 
To  study  whether  O4-mediated  conversion  of 
aggregation intermediates into stable amyloid fibrils 
influences  A42 toxicity,  SH-SY5Y  neuroblastoma 
cells  were  incubated  for  48  h  with  soluble  A42 
peptides and different concentrations of O4. Viability 
of  cells  was  examined  using  a  3-(4,5-
dimethylthiazol-2yl)-2,5-diphenyltetrazolium  bromide 
(MTT) assay  38.  We found that  incubation  of  cells 
with A42 peptides caused a pronounced inhibition of 
MTT reduction (~50%), indicative of impaired cellular 
metabolic  activity.  This  effect,  however,  was 
suppressed  when  O4  was  added  to  the  culture 
medium (Fig.  6a).  In  contrast,  the  compound  O8, 
which  does  not  promote  amyloid  fibrillogenesis  in 
cell-free  assays  (Supplementary  Table  2),  did  not 
rescue A42 toxicity (Supplementary Fig. 7a).
To investigate whether O4 treatment influences cell-
associated A42 aggregation, cell culture media were 
analyzed by SDS-PAGE and silver staining (Fig. 6b). 
In  untreated  samples,  relatively  large  amounts  of 
small A42 monomers and oligomers (~12 kDa) were 
detected.  The  abundance  of  these  structures, 
however, diminished in O4 treated samples. At the 
same time, O4 addition increased the abundance of 
larger  aggregate  structures,  suggesting  that  the 
compound promotes amyloidogenesis.  A reduction 
of  toxicity  was  also  observed  when  A42 treated 
primary  cortical  neurons  were  incubated  with  O4, 
confirming  the  results  with  the  SH-SY5Y 
neuroblastoma cells (Suppl.  Supplementary Fig. 7b 
and c).
Next,  we  examined  whether  O4-mediated 
stimulation  of  extracellular  amyloidogenesis 
influences intracellular aggregation of A42 peptides, 
which are readily taken up by mammalian cells. A42 
peptides labeled with the fluorescent dye Alexa 633 
were added to human neuroblastoma SH-EP cells in 
the presence and absence of O4 and formation of 
intracellular  aggregates  was  quantified  by 
immunofluorescence  microscopy  (Supplementary 
Fig. 7d). O4 treatment caused a 3-fold reduction of 
intracellular A42 aggregates compared to untreated 
controls  (Supplementary  Fig. 7e),  indicating  that 
compound-mediated  stimulation  of  extracellular 
amyloid  polymerization  alters  the  uptake  and 
intracellular formation of A42 aggregates.
Finally,  we  investigated  whether  O4  treatment 
influences A42-mediated impairment of hippocampal 
long-term potentiation (LTP) in rat brain slices 15,39. A 
preparation of  A42 peptides  containing monomers 
and  small  oligomers  was  added  to  hippocampal 
brain slices and LTP was measured in the CA1 area. 
In agreement with previous studies 39, we found that 
small A42 oligomers block LTP in brain slices (Fig. 
6c). This effect, however, was suppressed when O4 
was added to samples, suggesting that compound-
mediated  acceleration  of  aggregation  rescues  the 
A42-induced dysfunction of synaptic plasticity.
Discussion
Previous  investigations  have  demonstrated  that 
chemical  agents  can  be  used  to  perturb  amyloid 
formation pathways 22. Most of these studies focused 
on small molecules or -sheet breaker peptides that 
inhibit  or  slow  down  spontaneous  amyloid 
polymerization  1,40.  In a few studies compounds or 
small  peptides that  promote amyloid  fibrillogenesis 
have been found 11,41,42. However, it mostly remains 
unclear  whether  monomers,  oligomers  or 
protofibrillar  structures  are  specifically  targeted  by 
modulators of amyloid aggregation 43,44 and whether 
compound effects on certain aggregate species (e.g. 
protofibrils)  are  toxic  or  beneficial  for  mammalian 
cells 13. 
In this study, we have searched for small molecules 
that  promote  spontaneous  A42 assembly.  This 
undertaking was motivated by recent  observations 
that  small,  diffusible  aggregate  species  (oligomers 
and/or protofibrils) are more toxic for neuronal cells 
than mature fibrils or end-stage amyloid plaques 45. 
Accordingly,  compounds  that  target  small,  on-
pathway  aggregate  species  and  promote  their 
conversion  into  larger  fibrils  might  reduce 
neurotoxicity.  Utilizing a FRA45,  we discovered und 
that the natural dye orcein efficiently promotes A42 
polymerization  (Fig.  1b).  Orcein  is  a  compound 
mixture consisting of  14 related small molecules 23 
that  has  been  used  as  a  food coloring since  the 
Middle Ages. As the orcein components might have 
different  biological  activities,  we  searched for pure 
chemicals with similar properties, which lead to the 
identification of the small molecule O4 (2,8-bis-(2,4-
dihydroxy-phenyl)-7-hydroxy-phenoxazin-3-one) that 
very efficiently stimulated A42 polymerization.
Previous  studies  have  demonstrated  that  A42 
amyloidogenesis  is  a  highly  complex,  multistep 
process, which involves the sequential formation of 
different  types  of  amyloid  species  such  as 
oligomers,  protofibrils  and  mature  fibrils  45.  A42 
monomers first assemble into oligomers, which over 
time convert into protofibrils and long amyloid fibrils 
with  a  typical  -sheet  structure.  It  is  currently 
believed that small  -sheet-rich spherical oligomers 
are on-pathway precursors of protofibrils and fibrils 5, 
while unstructured (non--sheet-rich) A42 oligomers 
7 are most likely off-pathway aggregation products. 
However,  recent investigations showed that non--
sheet  A42 oligomers produced at low temperatures 
can convert into ordered  -sheet-rich amyloid fibrils 
at  higher temperatures  7.  Thus,  it  seems plausible 
that  spherical  A42 oligomers  with  different 
morphologies  and  structures  can  transform  into 
larger -sheet-rich amyloid aggregates.
Our  data  indicate  that  O4  binds  to  spherical,  on-
pathway  -sheet-rich A42 oligomers and promotes 
their conversion into larger amyloid fibrils (Fig. 2c-e 
and Supplementary Fig. 3a - e). This effect is most 
probably caused by an interaction of the compound 
with  hydrophobic  residues in  the central  region  of 
A42 peptides.  We suggest  that  O4 stimulates  the 
conversion of oligomers into amyloid fibrils because 
it  increases  the  hydrophobicity  on  the  surface  of 
amyloid  oligomers,  leading  to  more  efficient 
intermolecular  interactions  and  aggregation.  O4  is 
an  aromatic  compound  that  potentially  can  form 
stacking  interactions  with  the  hydrophobic 
phenylalanine  residues  F19  and  F20  in  A42 
peptides (Fig.  3a and c).  These amino acids were 
previously shown to be critical for efficient amyloid 
polymerization  in vitro 21. However, our data do not 
exclude the possibility that other hydrophobic amino 
acids in the  A42 peptide such as the glycines G33 
and  G37 are  also  important  for  the  conversion  of 
small  oligomers into protofibrils  and fibrils  (Fig.  3a 
and c). The exchange of glycines with other amino 
acids  has previously  been shown to  influence the 
rate of spontaneous amyloid polymerization 46.
Our  data  also  suggest  that  O4  directly  binds  to 
hydrophobic  regions  in  protofibrils  and  mature 
amyloid  fibrils  (Fig.  3).  This  is  supported  by 
computational  docking  studies,  predicting  that  the 
compound associates with hydrophobic grooves on 
the surface of amyloid structures (aa 20-21, 33-35, 
35-37) that run parallel to the long fibril axis (Fig. 5). 
Strikingly,  our docking studies also predict that O4 
requires 4-5  A42 molecules for its association with 
amyloid fibrils  (Fig.  5),  suggesting  that  the 
compound  promotes  fibrillogenesis  by  stabilizing 
small  -sheet-rich  protofibrillar  structures  that  lie 
directly  en  route to  fibril  formation.  Compound 
binding  to  protofibrils  and  fibrils  could  alter  the 
equilibrium  between  monomers,  oligomers, 
protofibrils and mature fibrils in dynamic aggregation 
reactions,  leading  to  the  accumulation  of  larger 
amounts  of  end-stage  amyloid  structures.  Our 
findings  that  O4-treated  amyloid  fibrils  are  more 
stable than untreated fibrils support this hypothesis 
(Fig. 2a and b). A model depicting the binding of O4 
to  small  -sheet-rich  structures  and  its  potential 
effects on amyloid polymerization is proposed in Fig. 
7.
A  comparison  of  our  results  with  previous 
investigations  on  aggregation  modulators  indicate 
that the mechanism of action of O4 is similar to that 
of  methylene  blue,  which  also  promotes  A42 
fibrillogenesis in cell-free assays 16. Interestingly, the 
authors of  that  study propose that  methylene blue 
influences  A42 oligomerization  and  fibrillogenesis 
independently and suggest that these two processes 
are not directly linked. We do not come to such a 
conclusion.  Rather,  our  data  indicate  that  A42 
oligomerization  and  fibrillogenesis  are  linked  and 
that  O4-mediated  stimulation  of  aggregation  is 
responsible  for  the  reduction  of  toxic,  on-pathway 
amyloid  oligomers.  However,  more  detailed  time-
resolved  studies  with  well-defined  A42 aggregate 
species  are  necessary  to  compare  the  results 
obtained with O4 and methylene blue.
While  O4 promotes  the  formation  of  long amyloid 
fibrils  the compound calmidazolium chloride (CLC) 
was shown to stabilize protofibrillar structures  13. A 
stabilization  of  -sheet-rich,  nontoxic,  spherical  A 
conformations  was  observed  with  the  compound 
scyllo-inositol  47,  while  the  polyphenol  EGCG  was 
shown  to  convert  A42 peptides  into  non-toxic, 
unstructured  oligomers  18.  A  similar  result  was 
obtained  more  recently  with  the  compound 
resveratrol  that  selectively  remodels  soluble 
oligomers  and  fibrils  of  A42 peptides  into  off-
pathway conformers  48.  Thus, small molecules can 
have different effects on A42 polymerization, leading 
to  the stabilization of  aggregate species with  very 
distinct conformations,  morphologies and biological 
properties.
Our  studies  indicate  that  the  compound  O4 
accelerates  A42 fibril  formation  and  thereby 
decreases  the  concentration  of  transient,  soluble 
A42 oligomers that  are toxic  for mammalian cells. 
Our  biochemical  and  cell-biological  investigations 
therefore  support  the  oligomer  toxicity  hypothesis, 
as  they  suggest  that  small  aggregates  appearing 
early in the amyloid formation cascade rather than 
large  fibrils  are  the  main  toxic  species  in  protein 
misfolding diseases 15. However, it currently remains 
unclear whether compound-mediated stimulation of 
amyloid  fibrillogenesis  in  vivo may  be  a  useful 
therapeutic  strategy  with  beneficial  effects  on 
neuronal  dysfunction.  For  instance,  it  needs to  be 
investigated  whether  the  chemical  compound  can 
influence  the  aggregation  of  low  nanomolar 
concentrations of A  peptides   in vivo. Moreover, it 
needs  to  be  seen  whether  compound-induced 
accelerated  deposition  of  A42 aggregates  has 
beneficial  effects  on  disease  pathogenesis  in  AD 
models.  Experimental  evidence  supporting  such  a 
view has been presented previously, indicating that 
accelerated  A fibrillization reduces oligomer levels 
and functional deficits in AD mouse models  49. We 
suggest  that compounds like O4, which bind to  -
sheet-rich  amyloid  structures  might  reduce  their 
toxicity  by  preventing the  abnormal  interactions  of 
small  aggregate  species  with  cellular  proteins. 
Moreover,  it  seems possible  that  compounds  that 
are bound to aggregates promote their degradation. 
Further  in  vivo studies with  AD transgenic  fly  and 
mouse  models  will  be  necessary  to  address  the 
question  of  whether  compounds  that  promote 
fibrillogenesis in vitro such as O4 may be useful for 
therapy development. 
Materials and Methods
Materials, toxicity assays and additional procedures 
are described in the Supplementary Methods.
Protein aggregation. 
For aggregation reactions, an Ab42 stock solution (1 
mM in DMSO) was diluted in phosphate buffer (100 
mM sodium phosphate, 10 mM NaCl, pH 7.4) to 15 
µM  and  incubated  in  1.5  ml  Eppendorf  tubes 
(Eppendorf,  Germany)  at  37°C.  Generation  of 
soluble Ab42 oligomers was performed as described 
30. Ab42 DMSO stock solutions were diluted in Ham’s 
F12 medium without  phenol  red at  a  final  peptide 
concentration  of  100  µM;  after  brief  vortexing 
samples  were  incubated  at  4  –  6°C  for  24  h. 
Alternatively,  Ab42  oligomers  were  prepared  as 
described in 28 by diluting DMSO stock solution to a 
final A42 concentration of 110 µM in 10 mM HEPES 
buffer pH 7.4.  Samples were incubated in a glass 
vial  with  a  micro  stir  bar  at  37°C  for  24  h  and 
subsequently  centrifuged  (Beckman  Coulter 
Microfuge  R,  rotor  F241.5P)  at  13,000  rpm.  All 
concentrations of  oligomeric  or  fibrillar  A species 
refer  to  the  equivalent  concentration  of  A 
monomers.
Quantification of insoluble amyloid 
aggregates. 
In  filter  retardation  assays  (FRAs)  60  µl  of  Ab42 
aggregation  reactions  were  added  to  an  equal 
volume of  4 % sodium dodecyl  sulfate (SDS) and 
100  mM  dithiothreitol  (DTT)  and  samples  were 
boiled at 98°C for 5 min. 85 µl of the heat denatured 
samples  were  filtered  through  a  cellulose  acetate 
membrane with 0.2 µm pores (OE66, Schleicher and 
Schuell,  Germany).  Membranes  were  blocked  in 
Tris-buffered  saline  containing  3  %  skim  milk. 
Aggregates  retained  on  the  filter  membrane  were 
detected using the 6E10 antibody (1 : 5,000; Sigma, 
Deisenhofen,  Germany)  and  secondary  antibodies 
conjugated  to  either  horseradish  peroxidase  or 
alkaline  phosphatase  (Promega,  Germany). 
Proteinase K (final  concentration of  10-200 µg/ml) 
was added to Ab42 aggregation reactions after 4 or 7 
d of incubation at 37°C. After incubation for 30 min 
at 37°C with proteinase K samples were denatured 
and analyzed by FRA.
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Figures
Fig.  1.  Identification  and  characterization  of  compounds that  accelerate  Aβ42 aggregation.  a,  Structural 
formula of O4. b, Effects of orcein or O4 on Aβ42 aggregate formation monitored by FRA. Aβ42 (15 µM) was 
incubated with orcein or O4 at equimolar concentrations or 5-fold molar excess; SDS-stable aggregates  
were  detected using the antibody 6E10.  c,  Analysis  of  O4  (150 µM)  treated  Aβ42 (15 µM)  aggregation 
reactions  by  TEM.  Bars  indicate  100  nm.  Arrows  indicate  oligomers  (white)  or  protofibrils  (black). d, 
Quantification of Aβ42 aggregate species observed after 48 h by TEM. e, Analysis of Aβ42 aggregates by CD 
spectroscopy.  Aβ42 (15 µM) aggregates were produced with an equimolar concentration of O4 at 37°C.  f, 
Change in ellipticity at 218 nm during incubation of monomeric Aβ42 (15 µM) with O4 (75 µM). CD data were 
fitted by monoexponential decay functions with time constants of  = 350 ± 30 nm (control) and  = 150 ± 40 
nm (O4). g Aβ42 (15 µM) aggregation monitored by Thioflavin T (ThT) fluorescence in the presence of O4-
generated seeds (1% v/v).  h, Treatment of 7PA2 cells with O4 (5 µM) stimulates the formation of SDS-
resistant Aaggregates. SDS-stable aggregates were detected by FRA (mAb 6E10).
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Fig.  2:  O4  binds  to  Aβ42 
oligomers and stimulates their 
conversion  into  SDS-stable 
fibrils.  a,  Analysis  of  O4-
generated  Aβ42 (15  µM) 
aggregate  species  by  SDS-
PAGE  and  silver  staining. 
Aggregates  were  produced  at 
37°C  during  48  h.  Lane  1: 
control without O4; Lanes 2-6: 
samples treated with  1.5,  7.5, 
15,  75  or  150  µM  O4;  M, 
monomer; D, dimer;  T, trimer; 
open  arrow,  medium-size 
oligomers;  filled  arrows,  large 
SDS-insoluble  aggregates.  b, 
Analysis  of  SDS-stable  Aβ42 
aggregates by FRA using the 
6E10  antibody.  Aβ42 peptides 
(15  µM)  were  incubated  with 
an equimolar  concentration of 
O4 and subsequently digested 
with  proteinase  K  (30  min  at 
37°C);  c,  Analysis  of  O4 
binding  to  Aβ42  (15  µM) 
aggregate species by dot  blot 
assays.  d, Quantitative 
analysis of O4 binding to  Aβ42 
oligomers.  Lines  represent 
fitting  by  a  cooperative  dose-
response  curve  with  a  Hill 
coefficient of 4. e,  Analysis of 
A42  (100  µM)  oligomerization 
by  TEM.  Peptides  were 
incubated with O4 (1 mM) for 
24h  at  6-8°C;  soluble 
aggregation  products 
(oligomers)  were  separated 
from  insoluble  material 
(protofibrils  and  fibrils)  by 
centrifugation.  Size  bars 
represent  100  nm.  f,  SDS-
PAGE  and  Western  blot 
analysis  of  O4  treated  Aβ42 
(110  M)  oligomers  after 
incubation  with  O4  for  24  h; 
anti-A antibody  57-11-4.  g, 
O4  treatment  reduces  the 
binding  of  anti-A A11 
antibody to  amyloid oligomers. 
Aβ42  peptides  (15  µM)  were 
incubated for 48 h with O4 and 
then  analyzed  by  dot  blot 
assays  using  the  6E10 
antibody.
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Fig. 3: O4 binds to hydrophobic regions in Aβ peptides. a, Incubation of a 10-mer peptide array with O4 (300 
µM). Peptide numbers represent the starting amino acid of 10-mer peptides. O4 binding to peptides was 
quantified colorimetrically. Two potential O4 binding regions in Aβ peptides were detected (peptides 8-16 
and 23-28). b, Interactions between Aβ40 peptide and O4 monitored by solution-state NMR spectroscopy. 2D 
1H,15N  correlation  spectrum  obtained  for  A40 in  presence  and  absence  of  O4.  The  inset  shows  a 
magnification of the spectrum with resonances of the hydrophobic core region of Aβ40 (residues 17-20).  c, 
Chemical  shift  changes  of  A upon  addition  of  O4,  employing  the  relation 
Dd tot=√ [Dd (1 H )]2+5 [Dd (15 N )]2 .
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Fig. 4: O4 changes the binding of anti-A antibodies to amyloid fibrils. a, Dot blot assays of O4 treated and 
untreated A42 (15 µM) aggregation reactions (5 d at 37°C). Aggregates were detected using the epitope-
specific  monoclonal  anti-A antibodies  6E10  (aa  4-9)  and  4G8  (aa  18-22),  respectively.  O4-treatment 
reduces the binding of 4G8 but not of 6E10 to amyloid fibrils. b, Bar graph quantification of triplicate samples 
± SD from a. c, Dot-blot assays of O4-generated Aβ42 aggregates using the fibril-specific antibody B10. Aβ42 
peptides (15 µM) were incubated for 48 h at 37°C with different concentrations of O4. O4 treatment reduces 
B10 binding to amyloid fibrils in a concentration-dependent manner. d, Bar graph quantification of triplicate 
samples ± SD from c. 
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Fig. 5: O4 binds to hydrophobic grooves on the surface of -sheet-rich A42 fibrils. a, Computational docking 
studies predict that O4 binds parallel to the long fibril axis targeting hydrophobic grooves at aa 33-35 or 35-
37. Binding to aa 33-35 and 35-37 was predicted to be mutually exclusive. b, Side view of an A42 fibril with 
O4 molecules bound to aa 20-21, 33-35 and 35-37. c, Predicted interaction of the oxazine ring in O4 with 
phenylalanine 20 (F20) in A42 fibrils.
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Fig. 6: O4-mediated acceleration of Aβ42 fibrillogenesis correlates with reduced cellular toxicity and improves 
synaptic transmission in brain slices.  a, O4 treatment reduces Aβ42 toxicity in a SHSY5Y cell model. Aβ42 
peptides (5 µM) and O4 were added to the culture medium of differentiated SHSY5Y cells and toxicity was 
monitored after an incubation period of 48 h using an MTT assay. O4 treatment improved cell viability in a 
concentration-dependent manner. b, Addition of O4 (5 µM or 25 µM) to SHSY5Y cell cultures promotes Aβ42 
(5 µM) aggregation, reducing the levels of soluble monomers and small oligomers. Samples were incubated 
for 48 h and analyzed by SDS-PAGE and silver staining. c, O4 treatment reduces Aβ42-induced inhibition of 
long-term potentiation  (LTP)  in  hippocampal  rat  brain  slices.  LTP of  excitatory  post-synaptic  potentials 
(EPSP) was evoked by high-frequency stimulation (HFS).
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Fig. 7: Working model of effects of O4 on spontaneous Aβ42 polymerization. a, Untreated, spontaneous Aβ42 
aggregation reaction. Seeding-competent, -sheet-rich Aβ42 aggregates (oligomers and protofibrils) are 
slowly formed during the nucleation (lag) phase by association of monomers. b, In O4 treated reactions 
formation of amyloid fibrils is accelerated because compound binding to -sheet-rich small aggregates 
stabilizes the formation of low molecular weight prefibrillar structures (tetramers, protofibrils etc.) that 
polymerize efficiently into mature amyloid fibrils. Thus, O4 treatment of heterogeneous Aβ42 aggregation 
reactions alters the kinetics of amyloid polymerization, leading to a reduced lag phase followed by a rapid 
exponential fibril growth phase (c). 
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